MG
TRDA icon

Michael Gelband’s Entrada Therapeutics TRDA Stock Holding History

Michael Gelband’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
52,767
+40,700
+337% +$390K ﹤0.01% 1300
2026
Q1 		$152K Sell
12,067
-25,363
-68% -$291K ﹤0.01% 1407
2025
Q4 		$385K Buy
+37,430
New +$315K ﹤0.01% 1247
2025
Q3 		– Sell
-15,785
Closed -$106K – 2028
2025
Q2 		$106K Buy
+15,785
New +$127K ﹤0.01% 1353
2025
Q1 		– Sell
-16,453
Closed -$284K – 1993
2024
Q4 		$284K Buy
16,453
+1,113
+7% +$20.2K ﹤0.01% 1292
2024
Q3 		$245K Sell
15,340
-184
-1% -$2.9K ﹤0.01% 1415
2024
Q2 		$221K Buy
+15,524
New +$221K ﹤0.01% 1381

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Michael Gelband's TRDA Position: Q2 2026 in Review

Michael Gelband increased its Entrada Therapeutics (TRDA) stake by 337% in Q2 2026, buying an estimated $390K and bringing the position to 52,767 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #1300.

Michael Gelband first reported a position in TRDA in Q2 2024 and has held it in 7 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Michael Gelband held 52,767 shares of Entrada Therapeutics worth $388K as of Q2 2026.
  • Michael Gelband bought 40,700 Entrada Therapeutics shares in Q2 2026, an estimated $390K.
  • Entrada Therapeutics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1300 holding.
  • Michael Gelband first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.